Abstract
The dopaminergic system plays a major role in neurological and psychiatric disorders such as Parkinsons disease, Huntingtons disease, tardive dyskinea and schizophrenia. Knowledge on altered dopamine synthesis, receptor densities and status are important for understanding the mechanisms underlying the pathogenesis and therapy of diseases. PET provides a non-invasive tool to investigate these features in vivo, provided the availability of suitable radiopharmaceuticals. To investigate presynaptic function, PET-tracers have been developed to measure dopamine synthesis and transport. For the former the most commonly used tracers are 6-[18F]FDOPA and 6-[18F]FMT, whereas for the latter several 11C/18F-labeled tropane analogues are being clinically used. Postsynaptically, dopamine exerts actions through several subtypes of the dopamine receptor. The dopamine receptor family consists of 5 subtypes D1-D5. In order to investigate the role of each receptor subtype, selective and high-affinity PETradioligands are required. For the dopamine D1-subtype the most commonly used ligand is [11C]SCH 23390 or [11C]NNC 112, whereas for the D2/D3-subtype [11C]raclopride is a common tracer. [18 F]Fallypride is a suitable PET-tracer for the investigation of extrapyramidal D2-receptors. For the other subtypes no suitable radioligands have been developed yet. This paper gives an overview of the current status on dopamine PET-tracers and the development of new lead compounds as potential PET-tracers by medicinal chemistry.
Keywords: positron emission tomography, dopamine receptor, dopamine transporter, Dopamine synthesis
Current Medicinal Chemistry
Title: PET Tracers for Imaging of the Dopaminergic System
Volume: 13 Issue: 18
Author(s): Kentaro Hatano, Kiichi Ishiwata and Philip H. Elsinga
Affiliation:
Keywords: positron emission tomography, dopamine receptor, dopamine transporter, Dopamine synthesis
Abstract: The dopaminergic system plays a major role in neurological and psychiatric disorders such as Parkinsons disease, Huntingtons disease, tardive dyskinea and schizophrenia. Knowledge on altered dopamine synthesis, receptor densities and status are important for understanding the mechanisms underlying the pathogenesis and therapy of diseases. PET provides a non-invasive tool to investigate these features in vivo, provided the availability of suitable radiopharmaceuticals. To investigate presynaptic function, PET-tracers have been developed to measure dopamine synthesis and transport. For the former the most commonly used tracers are 6-[18F]FDOPA and 6-[18F]FMT, whereas for the latter several 11C/18F-labeled tropane analogues are being clinically used. Postsynaptically, dopamine exerts actions through several subtypes of the dopamine receptor. The dopamine receptor family consists of 5 subtypes D1-D5. In order to investigate the role of each receptor subtype, selective and high-affinity PETradioligands are required. For the dopamine D1-subtype the most commonly used ligand is [11C]SCH 23390 or [11C]NNC 112, whereas for the D2/D3-subtype [11C]raclopride is a common tracer. [18 F]Fallypride is a suitable PET-tracer for the investigation of extrapyramidal D2-receptors. For the other subtypes no suitable radioligands have been developed yet. This paper gives an overview of the current status on dopamine PET-tracers and the development of new lead compounds as potential PET-tracers by medicinal chemistry.
Export Options
About this article
Cite this article as:
Hatano Kentaro, Ishiwata Kiichi and Elsinga H. Philip, PET Tracers for Imaging of the Dopaminergic System, Current Medicinal Chemistry 2006; 13 (18) . https://dx.doi.org/10.2174/092986706777935258
DOI https://dx.doi.org/10.2174/092986706777935258 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Ezogabine: Development and Role in the Management of Epileptic Seizures
Mini-Reviews in Medicinal Chemistry Prevention Interventions for People Living with HIV in Military Settings
Current HIV Research Involvement of Uridine-Nucleotide-Stimulated P2Y Receptors in Neuronal Growth and Function
Central Nervous System Agents in Medicinal Chemistry Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets Graphical Abstracts:
Current Angiogenesis (Discontinued) Combined Immunization of Mice with DNA, rMVA and rAd5 Expressing HIV-1 Structural Genes from Different Subtypes
Current HIV Research Pure Emotion-loaded Materials in the International Affective Digitized Sounds (IADS): A Study on Intensity Ratings in Chinese University Students
Current Psychiatry Research and Reviews Meet Our Editorial Board Member
Current Neuropharmacology Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders The New Challenges of Brain PET Imaging Technology
Current Medical Imaging Editorial (Thematic Issue: An Overwiew on the Chemistry and Biochemistry of Triterpenoids)
Mini-Reviews in Organic Chemistry Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Meet Our Editorial Board Member
Infectious Disorders - Drug Targets What can Actigraphy Add to the Concept of Labschool Design in Clinical Trials?
Current Pharmaceutical Design